Rocky Mountain Neurological Disorders Core Center

总体组成部分-项目摘要 落基山神经疾病中心核心（RMNDC）的主要目标是提供资源， 这将使安舒茨医学院的神经科学家能够将变革性技术融入到 他们的研究。在这里，我们的目标是相对较新的尖端神经科学工具， 那些将对我们正在进行的研究产生最大影响的研究，使研究人员能够将强大的 新的方法进入他们的研究计划，并促进新的合作。 我们提出了三个研究核心（A，光遗传学和神经工程; B，纳米显微镜; C， 行为和体内神经生理学），这将提供强大的工具，战略性地推进影响 我们神经科学界的研究和生产力。新的核心将提供服务， 在校园的其他地方。此外，这些核心侧重于具有高影响力的研究工具， 用于我们的神经科学社区。我们优先为核心配备设备和工具专家 因此，没有经验的研究人员将能够将新方法纳入他们的研究中。 适当地研究项目，并达到最严格的标准。 总的来说，核心将开辟新的研究途径，这对正在进行的工作至关重要。 当前44个RMNDC PI。因此，核心将促进有关基本机制的研究， 神经系统的发展和功能，需要找到创新和更有效的治疗方法， 神经系统疾病

Overall Component – Project Summary The primary goal of the Rocky Mountain Neurological Disorders Center Core (RMNDC) is to provide resources that will allow neuroscientists on the Anschutz Medical Campus to incorporate transformative technologies into their research. Here, we target cutting edge neuroscience tools that are relatively new and considered to be those that will have the highest impact on our on-going research, allow investigators to incorporate powerful new approaches into their research programs and catalyze new collaborations. We propose three Research Cores (A, Optogenetics & Neural Engineering; B, Nanoscopy; C, Behavioral and In Vivo Neurophysiology) that will provide powerful tools that advance strategically the impact of the research and productivity of our neuroscience community. The new Cores will provide services not available elsewhere on campus. Moreover, these Cores focus on research tools that are of high impact and use to our neuroscience community. We prioritize staffing the Cores with experts in the equipment and tools so that investigators without prior experience will be in a position to incorporate new methods into their research programs appropriately and to the most exacting standards. Overall, the Cores will open up new avenues of research that are essential for on-going work of the current 44 RMNDC PIs. Thus, the Cores will promote research regarding fundamental mechanisms underlying nervous system development and function that is required to find innovative and more effective treatments for neurological disease.